Credit Suisse released a report on Apollo Hospitals on September 24 and said that the company has a "outperform" rating and raised its target price aggressively to Rs 2,365 versus the earlier target of Rs 1,775.

Share Market Live

NSE

Credit Suisse believes that the pharma business of Apollo Hospital is highly underappreciated. The ratings agency added that major a contribution to Apollo will come from the asset light side of businesses, which will contribute at least 45 percent of EBITDA by FY25. Credit Suisse expects the RoC to double to 25 percent by FY25. CNBC-TV18's Nimesh Shah shares the key highlights from the report.

To watch other videos in this series, click the Standout Brokerage Reports tab below.